Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Danielle Manes

Physician Assistant, Medical Austin, TX Physician Assistant

NPI 1073842696 CMS profile 10637267

11410 Jollyville Rd Ste 1101, Austin, TX 78759

Open in the dashboard

General payments

$9,916

536 records reported · program years 2021–2025

Research payments

$210

Paid to them · 1 record reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Danielle Manes of Austin, TX is reported in the CMS Open Payments database as having received $9,916 across 536 general payments and $210 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,376 110
2024 General $2,271 114
2023 General $2,185 122
2022 General $1,695 102
2022 Research $210 1
2021 General $1,389 88

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Danielle Manes
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Danielle Manes were reported at $2,376. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Danielle Manes Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $1,389 $156 $41–$563 $132
2022 $1,695 $185 $55–$649 $149
2023 $2,185 $199 $58–$717 $160
2024 $2,271 $206 $62–$740 $164
2025 $2,376 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Medtronic, Inc. $2,475 136 payments
  2. Sumitomo Pharma America, Inc. $2,045 132 payments
  3. AbbVie, Inc. $1,182 60 payments
  4. Urovant Sciences Inc $538 41 payments
  5. Janssen Biotech, Inc. $513 20 payments
  6. Astellas Pharma US Inc $369 17 payments
  7. Ferring Pharmaceuticals Inc. $219 11 payments
  8. Coloplast Corp $203 7 payments
  9. Bayer HealthCare Pharmaceuticals Inc. $197 9 payments
  10. Allergan Inc. $188 13 payments
  11. Other $1,986 90 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $9,593 531 payments
  2. Education $292 4 payments
  3. Travel and Lodging $30 1 payment
Products named General payments · program years 2021–2025
  1. GEMTESA $2,491 169 payments
  2. INTERSTIM $2,445 135 payments
  3. BOTOX Botox Therapeutic $803 40 payments
  4. ERLEADA $537 21 payments
  5. BOTOX Hyperhydrosis $423 25 payments
  6. ADSTILADRIN $219 11 payments
  7. Nubeqa $197 9 payments
  8. iTIND System $183 11 payments
  9. PROVENGE $181 6 payments
  10. MYRBETRIQ $173 12 payments
  11. Other $2,746 124 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2021–2025
  1. Medtronic, Inc. $210 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 38 drugs

Part D claims

2,377

Median for Physician Assistant: 241

Drug cost

$486,820

Median for Physician Assistant: $4,110

Branded share of claims

47.2%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gemtesa Vibegron Brand 298 $230,654
Myrbetriq Mirabegron Brand 178 $144,795
Mirabegron Er Mirabegron Brand 47 $34,358
Estradiol Generic 278 $13,565
Osphena Ospemifene Brand 44 $13,262
Methenamine Hippurate Generic 105 $7,267
Premarin Estrogens, Conjugated Brand 13 $6,797
Progesterone Progesterone, Micronized Brand 81 $5,523
Nitrofurantoin Nitrofurantoin Macrocrystal Brand 137 $5,060
Solifenacin Succinate Generic 101 $4,285

The 10 drugs with the highest cost, of 38 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 30 billing codes

Paid by Medicare

$109,938

Of which drugs: $13,561

Medicare patients

466

Average age 76

Services billed

5,975

440 women, 26 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 67%
Arthritis 59%
Osteoporosis 30%
Ischemic heart disease 28%
Depression 28%
Diabetes 23%
Atrial fibrillation 17%
Cancer 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, onabotulinumtoxina, 1 unit J0585 Office 17 2,700 $13,458

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
GEMTESA
  • Sumitomo Pharma America, Inc. $606
$606 298 —
BOTOX
  • AbbVie, Inc. $297
$297 — 2,700
ADSTILADRIN
  • Ferring Pharmaceuticals Inc. $122
$122 — —
LYNPARZA
  • Merck Sharp & Dohme Corporation $59
  • AstraZeneca Pharmaceuticals LP $25
$84 — —
INTRAROSA
  • MILLICENT US INC $35
$35 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

537 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record